tbuckley/cabot-search huggingface dataset:
Clinical Features and Burden of Postacute Sequelae of SARS-CoV-2 Infection in Children and Adolescents
Authors: Suchitra Rao, Grace M. Lee, Hanieh Razzaghi, Vitaly Lorman, Asuncion Mejias, Nathan M. Pajor, Deepika Thacker, Ryan Webb, Kimberley Dickinson, L. Charles Bailey, Ravi Jhaveri, Dimitri A. Christakis, Tellen D. Bennett, Yong Chen, Christopher B. Forrest
Journal: JAMA Pediatrics (2022)

The postacute sequelae of SARS-CoV-2 infection (PASC) has emerged as a long-term complication in adults, but current understanding of the clinical presentation of PASC in children is limited.To identify diagnosed symptoms, diagnosed health conditions, and medications associated with PASC in children.This retrospective cohort study used electronic health records from 9 US children's hospitals for individuals younger than 21 years who underwent antigen or reverse transcriptase-polymerase chain reaction (RT-PCR) testing for SARS-CoV-2 between March 1, 2020, and October 31, 2021, and had at least 1 encounter in the 3 years before testing.SARS-CoV-2 positivity by viral test (antigen or RT-PCR).Syndromic (symptoms), systemic (conditions), and medication PASC features were identified in the 28 to 179 days following the initial test date. Adjusted hazard ratios (aHRs) were obtained for 151 clinically predicted PASC features by contrasting viral test-positive groups with viral test-negative groups using proportional hazards models, adjusting for site, age, sex, testing location, race and ethnicity, and time period of cohort entrance. The incidence proportion for any syndromic, systemic, or medication PASC feature was estimated in the 2 groups to obtain a burden of PASC estimate.Among 659 286 children in the study sample, 348 091 (52.8%) were male, and the mean (SD) age was 8.1 (5.7) years. A total of 59 893 (9.1%) tested positive by viral test for SARS-CoV-2, and 599 393 (90.9%) tested negative. Most were tested in outpatient testing facility settings (322 813 [50.3%]) or office settings (162 138 [24.6%]). The most common syndromic, systemic, and medication features were loss of taste or smell (aHR, 1.96; 95% CI, 1.16-3.32), myocarditis (aHR, 3.10; 95% CI, 1.94-4.96), and cough and cold preparations (aHR, 1.52; 95% CI, 1.18-1.96), respectively. The incidence of at least 1 systemic, syndromic, or medication feature of PASC was 41.9% (95% CI, 41.4-42.4) among viral test-positive children vs 38.2% (95% CI, 38.1-38.4) among viral test-negative children, with an incidence proportion difference of 3.7% (95% CI, 3.2-4.2). A higher strength of association for PASC was identified in those cared for in the intensive care unit during the acute illness phase, children younger than 5 years, and individuals with complex chronic conditions.In this large-scale, exploratory study, the burden of pediatric PASC that presented to health systems was low. Myocarditis was the most commonly diagnosed PASC-associated condition. Acute illness severity, young age, and comorbid complex chronic disease increased the risk of PASC.
The emotion regulation process in somatic symptom disorders and related conditions - A systematic narrative review
Authors: Katharina Schnabel, Tara Marlena Petzke, Michael Witthöft
Journal: Clinical Psychology Review (2022)

Somatic symptom disorders and related conditions (SSD-RC), along with depression and anxiety disorders, are among the most common mental disorders. Disturbances in emotion regulation (ER) are considered a key factor in the etiology and pathogenesis of SSD-RC. The present review aims to summarize relevant research on ER in SSD-RC and integrate results in the extended process model of ER. We conducted a systematic literature search in PubMed, PsycInfo, Psyndex, and Web of Science. After screening and systematic quality appraisal, 105 (n = 29332 participants) out of 2118 identified studies were included. Correlations with somatic symptoms in general and clinical populations as well as group comparisons with non-SSD-RC groups were included to summarize effects. We found evidence for deficits in the identification process of ER, especially reduced emotional clarity and ER self-efficacy, in patients with SSD-RC. SSD-RC were also significantly associated with a deviant pattern of habitual strategies (selection process) including a more frequent use of expressive suppression and a less frequent use of cognitive reappraisal. However, for both the identification and selection stages, there were many studies that did not find evidence for alterations in SSD-RC. Furthermore, self-report data suggests impairments in implementing ER. Experimental studies are scarce and have not found conclusive evidence for ER implementation deficits in SSD-RC. In addition to experimental studies, particularly ecological momentary assessments are needed to better understand potential alterations regarding ER in SSD-RC. Clinical interventions that target the identification of the need for ER, self-efficacy, and the repertoire of different strategies currently appear most promising.
Response to ‘Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable’
Authors: Mark B. Faries, Alistair J. Cochran, John F. Thompson
Journal: British Journal of Dermatology (2022)

Abstract Linked article: Dixon et al. Br J Dermatol 2022; https://doi.org/10.1111/bjd.21712
<scp>Tyrosine kinase inhibitors</scp> dosing for chronic phase <scp>chronic myeloid leukemia</scp>: The case for starting low with dasatinib (50 mg/day) and ponatinib (15 mg/day)
Authors: Ayalew Tefferi, Kebede H. Begna, Kristen B. McCullough
Journal: American Journal of Hematology (2022)

The data that support the findings of this article are available from the corresponding author upon reasonable request.
Electroencephalogram in the intensive care unit: a focused look at acute brain injury
Authors: Ayham Alkhachroum, Brian Appavu, Satoshi Egawa, Brandon Foreman, Nicolas Gaspard, Emily J. Gilmore, Lawrence J. Hirsch, Pedro Kurtz, Virginie Lambrecq, Julie Kromm, Paul Vespa, Sahar F. Zafar, Benjamin Rohaut, Jan Claassen
Journal: Intensive Care Medicine (2022)
Flat Silk Cocoon‐Based Dressing: Daylight‐Driven Rechargeable Antibacterial Membranes Accelerate Infected Wound Healing
Authors: Shixiong Yi, Ying Zhou, Jiamei Zhang, Min Wang, Shaohui Zheng, Xiao Yang, Lian Duan, Rui L. Reis, Fangyin Dai, Subhas C. Kundu, Bo Xiao
Journal: Advanced Healthcare Materials (2022)

Abstract One of the leading causes of death globally, especially in underdeveloped countries, is bacterial infection. Recently, the prevalence of infections from antibiotic‐resistant bacteria has been increasing, which makes the need for innovative antibacterial wound dressings urgent. It is reported that g‐C 3 N 4 ‐based flat silk cocoons (FSCs) with rechargeable antibacterial activity can efficiently generate reactive oxygen species (ROS) under daylight irradiation. The photoactive FSCs store the ROS and then release them in the dark. The engineered FSCs exhibit integrated properties of good biocompatibility, strong mechanical characteristics, robust photoactivity with photostorability, and excellent bactericidal efficiency (99.9% contact killing). In a rat model of infected wounds, the photoactive FSCs induce faster healing and reduce bacterial infections. The successful application of these FSC materials as wound dressings may provide a versatile platform for exploring the use of green photoactive antibacterial materials for accelerated wound healing and prevention of infections.
A biomimetic multilayered polymeric material designed for heart valve repair and replacement
Authors: Mingze Sun, Mohamed Elkhodiry, Lei Shi, Yingfei Xue, Maryam H Abyaneh, Alexander P Kossar, Caroline Giuglaris, Samuel L Carter, Richard L Li, Emile Bacha, Giovanni Ferrari, Jeffrey Kysar, Kristin Myers, David Kalfa
Journal: Biomaterials (2022)
High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure After Extubation and Liberation From Respiratory Support in Critically Ill Children—Reply
Authors: Padmanabhan Ramnarayan, Karen Thomas, Paul Mouncey
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development and External Validation of a Model Predicting <scp>New‐Onset</scp> Chronic Uveitis at Different Disease Durations in Juvenile Idiopathic Arthritis
Authors: Joeri W. van Straalen, Lianne Kearsley‐Fleet, Jens Klotsche, Sytze de Roock, Kirsten Minden, Arnd Heiligenhaus, Kimme L. Hyrich, Joke H. de Boer, Lovro Lamot, Alma N. Olivieri, Romina Gallizzi, Elzbieta Smolewska, Enrique Faugier, Serena Pastore, Philip J. Hashkes, Cristina N. Herrera, Wolfgang Emminger, Rita Consolini, Nico M. Wulffraat, Nicolino Ruperto, Joost F. Swart
Journal: Arthritis & Rheumatology (2022)

To develop and externally validate a prediction model for new-onset chronic uveitis in children with juvenile idiopathic arthritis (JIA) for clinical application.
Review of the Diagnosis and Management of Lumbar Spinal Stenosis—Reply
Authors: Jeffrey N. Katz, Melvin C. Makhni
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Review of the Diagnosis and Management of Lumbar Spinal Stenosis
Authors: Manuela L. Ferreira, Rachelle Buchbinder, Gavin A. Davis
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pricing of Drugs With Evidence Development
Authors: Michael K. Gusmano, David Chinitz, Victor Rodwin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Authors: Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali, Stacey M. Fernandes, Alberto J. Arribas, Abdul K. Hilli, Kjetil Taskén, Francesco Bertoni, Anthony R. Mato, Emmanuel Normant, Jennifer R. Brown, Geir E. Tjønnfjord, Tero Aittokallio, Sigrid S. Skånland
Journal: Clinical Cancer Research (2022)

PI3K inhibitors (PI3Ki) are approved for relapsed chronic lymphocytic leukemia (CLL). Although patients may show an initial response to these therapies, development of treatment intolerance or resistance remain clinical challenges. To overcome these, prediction of individual treatment responses based on actionable biomarkers is needed. Here, we characterized the activity and cellular effects of 10 PI3Ki and investigated whether functional analyses can identify treatment vulnerabilities in PI3Ki-refractory/intolerant CLL and stratify responders to PI3Ki.
Monoclonal Antibody Overcomes Migraine Treatment Failure
Authors: Anita Slomski
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pricing of Drugs With Evidence Development—Reply
Authors: James C. Robinson
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
High-Flow Nasal Cannula Therapy vs Continuous Positive Airway Pressure After Extubation and Liberation From Respiratory Support in Critically Ill Children
Authors: Yanfei Shen, Guolong Cai, Jing Yan
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Trends in Lipid Concentrations and Lipid Control Among US Adults, 2007-2018
Authors: Rahul Aggarwal, Deepak L. Bhatt, Fatima Rodriguez, Robert W. Yeh, Rishi K. Wadhera
Journal: JAMA (2022)

High lipid concentrations are a modifiable risk factor for cardiovascular disease. Little is known about how population-level lipid concentrations, as well as trends in lipid control, have changed over the past decade among US adults.
Risk of Arrhythmia Among New Users of Hydroxychloroquine in Rheumatoid Arthritis and Systemic Lupus Erythematosus: A <scp>Population‐Based</scp> Study
Authors: M. Rashedul Hoque, Leo Lu, Narsis Daftarian, John M. Esdaile, Hui Xie, J. Antonio Aviña‐Zubieta
Journal: Arthritis & Rheumatology (2022)

We assessed the association between hydroxychloroquine (HCQ) initiation and risk of arrhythmia among patients with incident rheumatoid arthritis (RA) or with incident systemic lupus erythematosus (SLE).All patients with incident RA or SLE and no arrhythmic events, not receiving antiarrhythmic medications, and not receiving HCQ prior to the index date of disease in British Columbia, Canada, between January 1996 and December 2014 were identified from administrative databases. We identified patients who were dispensed HCQ prescriptions (HCQ initiators) or were not dispensed HCQ prescriptions (HCQ noninitiators) during each study year; groups were matched 1:1 by propensity scores using baseline confounders on demographics, comorbidities, medications, and health care utilization. Outcomes were any new arrhythmias, atrial fibrillation, abnormal electrocardiograms, including long QT syndrome and conduction disorder, and other unspecified arrhythmias during follow-up. We used cause-specific Cox proportional hazards models with death as a competing event to assess the association between HCQ initiation and the outcomes.We identified 11,518 propensity score-matched patients with RA or SLE in each group. Over the mean follow-up of 8 years, there were 1,610 and 1,646 incident arrhythmias in the HCQ initiator group and the noninitiator group, respectively, with crude incidence rates of arrhythmia of 17.5 and 18.1 in 1,000 persons per year, respectively. The adjusted cause-specific hazard ratio (cHR) for patients who received HCQ was 0.96 (95% confidence interval [95% CI] 0.89-1.03) compared with HCQ noninitiators, and the cHRs for patients who took HCQ and had arrhythmia subtypes of atrial fibrillation, abnormal electrocardiograms, and other unspecified arrhythmias were 0.93 (95% CI 0.83-1.04), 0.98 (95% CI 0.87-1.11), and 0.95 (95% CI 0.84-1.07), respectively.Risk of any type of arrhythmia was not increased among new users of HCQ.